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1. Introduction 
Neuroendocrine tumors comprise a spectrum of slow growing neoplasm, characterized by 
storage and secretion of variable peptides and neuroamines (Massironi et al., 2008). 
Pancreatic neuroendocrine tumors (PNET) are relatively rare, with an estimated incidence of 
less than 1 per 1000,000 individuals (Metz and Jensen, 2008). A recent review of surveillance 
epidemiology and end results (SEER) (1950-2007) database reported the frequency of PNET 
to be around 7% among all identified neuroendocrine tumors (Lawrence et al., 2011a). 
Furthermore, they comprise 1-2% of all pancreatic neoplasms (Metz and Jensen, 2008). 
However, the incidence is considered to be increasing , perhaps in part due to improved 
diagnostic capabilities. Median overall survival in PNET ranges from more than 10 years in 
localized disease to approximately 2 years in metastatic disease (Yao et al., 2008a). Recently, 
considerable headway has been made in the realm of therapeutics. Therefore, it is 
imperative that oncologists today have a heightened awareness of this disease entity in 
order to provide effective care. 
2. Diagnosis, staging and classification 
PNETs have also been referred to as pancreatic endocrine or islet cell tumors. It is important 
to note that carcinoid and PNETs, although exhibiting identical characteristics histologically, 
should be considered separately. It is increasingly clear that these two tumor types are 
different in their biology and response to therapy. The clinical presentation of PNET is 
extremely variable which depends on the originating cell type and whether there is 
secretion of active hormones. Majority of patients remain asymptomatic, but a significant 
proportion present with clinical symptoms and hepatic metastases at the time of diagnosis 
(Modlin et al., 2008).  
Most cases of PNET occur sporadically, however, approximately 10% of cases may be 
associated with multiple endocrine neoplasia type 1 (MEN1). MEN1 is an autosomal 
dominant syndrome associated with mutations in the tumor suppressor gene menin and 
characterized by multiple neuroendocrine tumors in the pancreas, parathyroid and pituitary 
glands (Agarwal et al., 2004). PNETs have also been associated with MEN2, Von Hippel-
Lindau disease, Tuberous sclerosis and Neurofibromatosis (Kulke et al., 2011). Although the 
incidence of these inherited syndromes is low, it may be important to consider these 
syndromes in the diagnostic work up of patients with PNETs. 
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It is important to discern the diagnosis of PNET from the more common pancreatic 
adenocarcinoma. Grossly, PNETs are solitary well demarcated, tan soft tumors which can 
have a nodular appearance, when they exhibit fibrosis. The histological criteria for diagnosis 
are well established. These tumors can range from well differentiated ,low grade tumors to 
more poorly differentiated high grade types. Well differentiated tumors can exhibit various 
histological patterns, ranging from a common solid nesting, trabecular to tubular-acinar and 
mixed patterns .The cells are characterized by round to ovoid shape, with eosinophilic 
granular cytoplasm and prominent nucleoli. Unusual types can exhibit a spindle cell 
morphology which is referred to as the “rhabdoid” type. High grade malignancies with high 
mitotic rate usually encompass large cell and small cell carcinomas (Asa, 2011).  
The usually employed classification schemes, although inconsistent in their criteria, reflect a 
basic separation between more indolent, well differentiated and aggressive poorly 
differentiated ones. While a number of histologic classification systems have been proposed 
for PNET, tumors with high mitotic count (>20/10 high power field) or a Ki-67 proliferation 
rate of >20%, generally represent highly aggressive malignancies and should be evaluated 
apart from the more classic well differentiated tumors such as classic carcinoid or islet cell 
type. These high grade malignancies are generally treated according to small cell carcinoma 
guidelines (Asa, 2011; Kloppel et al., 2004; Rindi and Kloppel, 2004). Table 1 outlines the 
histologic classification of neuroendocrine tumors.  
Differentiation Mitotic 
count 
Grade Ki-67 
index (%) 
General features ENETS, WHO 
classification 
Well 
differentiated 
<2 per 
10 HPF 
Low Grade 
(G1) 
<2 Without local 
invasion 
(angioinvasion or 
perineural 
invasion). 
Traditionally 
include carcinoid 
and PNETs 
Neuroendocrine 
tumor grade 1, 
WHO type 1.1 
(pancreatic)  
 2-20 per 
10 HPF 
Intermediate 
grade (G2) 
3-20 With or without 
gross local invasion 
or metastases. 
Traditionally 
include carcinoid, 
atypical carcinoid 
and some PNET 
Neuroendocrine 
tumor, Grade 2, 
WHO type 1.2 
and 2 
(pancreatic) 
Poorly 
Differentiated 
>20 per 
10 HPF 
High Grade 
(G3) 
>20 % Small cell or large 
cell carcinoma, 
often widely 
invasive or 
metastatic.  
Neuroendocrine 
Carcinoma 
grade 3 (small 
cell or large 
cell), WHO type 
3 (pancreatic) 
ENETS: European Neuroendocrine Tumor Society; WHO: World Health Organization. 
Table 1. Histologic classification of Neuroendocrine Tumors. 
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Several organizations, including the European Neuroendocrine Tumor Society (ENETS), 
and the American Joint Committee on Cancer (AJCC), have proposed staging systems for 
neuroendocrine tumors using the TNM notation (Edge and Compton, 2010). Although these 
two staging systems are similar for tumor arising in the luminal gut, they differ for earlier 
stage PNETs. The ENETS system incorporates tumor diameter in its assessment for T stage, 
whereas the AJCC incorporates factors determining resectability. However, both systems 
are nearly identical in defining stage IV disease. Because the AJCC system has been widely 
accepted and adopted in North America, this is preferably and more commonly used for 
classification by tumor stage. 
3. Clinical manifestation 
When functional, PNETs can be characterized by the type of hormone secreted leading to a 
specific clinical manifestation (Table 2). Specific details about some common tumors, based 
on the presentation are discussed below. 
3.1 Insulinoma 
Insulinomas are the most common PNET, comprising 30-40% of these tumors. Overall, they 
remain a rare entity with an incidence of approximately 0.4/100,000 patient years (Mathur et 
al., 2009).Classically, they present with “Whipple’s Triad”: a combination of symptoms of 
hypoglycemia, inappropriately high insulin level and associated blood glucose levels of <50 
mg/dl with relief of symptoms on administration of glucose (Whipple and Frantz, 1935). In 
a 25-year Massachusetts General Hospital experience with insulinoma, the most common 
clinical symptoms in this series of 61 patients were confusion, visual disturbances and 
diaphoresis (Nikfarjam et al., 2008). Biochemical diagnosis requires confirmation of 
inappropriately elevated insulin, C-peptide and proinsulin levels in the presence of low 
serum glucose. Biochemical diagnosis is usually followed by radiological (CT or MRI) or 
endoscopic diagnosis. At early stages, the hypoglycemia can be managed with diazoxide 
and somatostatin analogues should be used cautiously as it can worsen hypoglycemia 
(Goode et al., 1986). Everolimus, an mTOR inhibitor, has been reported to be efficacious in 
cases of refractory hypoglycemia (Kulke et al., 2009a).  
3.2 Gastrinoma 
Gastrinoma and Zollinger-Ellison syndrome are suspected in a patient with recurrent or 
refractory peptic ulcer disease and unexplained secretory diarrhea. In such patients, fasting 
gastrin level >100 pg/ml is highly suspicious of this diagnosis (Jensen, 1996). Other common 
causes of gastric hypersecretion should be excluded, which includes treatment with proton 
pump inhibitors (PPI), atrophic gastritis and pernicious anemia. Approximately 25% of 
patients will present with diarrhea as primary manifestation without peptic ulcer disease 
(Perry and Vinik, 1995). Gastrinomas have a strong predilection for a “gastrinoma triangle” 
that includes the pancreatic head, first two-thirds of the duodenum and the porta hepatis 
(Howard et al., 1990). A significant proportion of gastrinomas are malignant, with up to one-
third of patients presenting with liver metastases (Mittendorf et al., 2006). PPI therapy is 
highly effective for initial symptom management and somatostatin analogues have also 
shown effectiveness in controlling symptoms and concomitantly offering tumor stabilization 
(Lambers et al., 1984; Shojamanesh et al., 2002).  
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3.3 Glucagonoma 
Majority of the patients with glucagonomas present with a dermatitis called necrolytic 
migratory erythema, causing pruritis and often becoming secondarily infected (Perry and 
Vinik, 1995). The clinical manifestation may also include diabetes, depression and deep vein 
thrombosis. Glucagonomas are frequently found in the pancreatic tail and have a malignant 
potential with a predilection for metastases. A serum glucagon level >500 pg/ml is highly 
suspicious of the diagnosis, whereas, a concentration of >10,000 pg/ml is virtually 
diagnostic (Chastain, 2001). However, a normal level does not exclude the diagnosis as 
secretion of glucagon may be episodic and a high concentration may be seen in other clinical 
syndromes such as sepsis, renal and hepatic failure. Initial management with somatostatin 
analogues are usually very effective in controlling symptoms however, such treatment may 
not have an effect on tumor growth. (Jockenhovel et al., 1994) 
3.4 Somatostatinoma 
Pancreatic somatostatinoma are usually malignant, and can present clinically with a 
syndrome of diabetes, steatorrhea and cholelithiasis (Warner, 2005). The diagnosis can be 
confirmed biochemically with marked elevation of serum somatostatin followed by imaging 
and endoscopic ultrasound, as with other pancreatic neuroendocrine tumors. Management 
with somatostatin analogues may be effective in symptomatic patients.  
3.5 VIPoma 
Verner and Morrison first described pancreatic endocrine tumors with a clinical syndrome 
of watery diarrhea, hypokalemia and achlorohydria (Verner and Morrison, 1958). This 
syndrome was subsequently found to be due to ectopic vasoactive intestinal peptide (VIP) 
secretion. Biochemical analysis assists in establishing a diagnosis when a marked elevation 
(>200 pg/dl) in the serum level of VIP is found (Smith et al., 1998). Symptomatic control of 
the diarrhea can be achieved with somatostatin analogues (Kraenzlin et al., 1985). 
Tumor Type Symptoms or signs Incidence of metastases 
Insulinoma Hypoglycemia leading to 
confusion, visual disturbance, 
diaphoresis. 
<15% 
 (Vinik and Gonzales, 
2011) 
Gastrinoma  
 (Zollinger-Ellison 
Syndrome) 
Abdominal pain, diarrhea 
(secretory), recurrent peptic ulcer 
disease 
50-85% (Batcher et al., 
2011; 
Mittendorf et al., 2006) 
Glucagonoma  Diabetes, necrotizing migratory 
erythema, cachexia, depression, 
deep vein thrombosis 
75% 
 (Batcher et al., 2011) 
VIPoma, Verner-Morrison 
syndrome,WDHA syndrome 
Watery diarrhea (secretory), 
hypokalemia 
70-80% (Vinik and 
Gonzales, 2011) 
Somatostatinoma Cholelithiasis, steatorrhea, 
diabetes 
80% (Vinik and 
Gonzales, 2011) 
Non-functioning Abdominal pain, weight loss, 
jaundice 
60-85% (Vinik and 
Gonzales, 2011) 
WDHA: Watery diarrhea, hypokalemia and achlorohydria 
Table 2. Clinical manifestation of Pancreatic Neuroendocrine Tumors. 
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4. Biochemical testing in PNET 
As majority of PNETs are non-functional, hormonal assays cannot be used for clinical 
assessment. Hence, serum chromogranin A (CgA) has come to represent a common 
denominator peptide with the putative ability to serve as a marker of disease activity, in both 
functional and non functional tumors. Granins are found as major components of the soluble 
core of dense secretory granules in neuroendocrine cells and are secreted in a physiologically 
regulated manner (Kim et al., 2001). Eight members have been identified including CgA, 
chromogranin B, chromogranin C, SgIII, SgIV, SgV, SgVI and VGF nerve growth factor-
inducible. Granins have been proposed as playing important roles in secretory granule 
formation and development. CgA was the initial member identified, and originally detected in 
the chromaffin granules of the adrenal medulla (Blaschko et al., 1967). Although the definitive 
function of CgA remains unclear, CgA derived peptides mediate a number of biologic 
functions including regulation of parathyroid hormone secretion, carbohydrate metabolism, 
lipid metabolism and catecholamine secretion etc (Lawrence et al., 2011b).  
Serum concentrations of CgA may decrease in patients responding to somatostatin analogs 
or other therapies. CgA should be used with caution as a marker of disease activity in 
patients treated with somatostatin analogs, because these agents significantly reduce plasma 
CgA levels which may falsely reflect any change in tumor size. Increased CgA 
concentrations assist in the clinical evaluation of PNETs but they are not specific for this 
kind of malignancy. Benign causes of CgA elevation should also be taken into consideration 
which include renal insufficiency, liver diseases and in patient taking proton pump 
inhibitors. Therefore, use of CgA as a diagnostic or screening test for PNET is discouraged. 
5. Conventional imaging and Somatostatin Receptor Scintigraphy (SRS) 
Although conventional imaging which include CT or MRI scans are usually employed in the 
initial diagnostic workup, they detect less than 50% of most PNETs that are less than 1 cm, 
therefore frequently missing small tumors (especially insulinomas, duodenal gastrinomas) 
and small liver metastases (Noone et al., 2005; Rockall and Reznek, 2007). Although, CT 
imaging with contrast is perhaps the most common initial imaging obtained, in certain 
clinical scenarios endoscopic ultrasound (EUS) paired with fine needle aspiration, remains 
the main endoscopic diagnostic technique. Several small studies reveal impressive 
diagnostic capability of this modality with reported sensitivity between 80% and 90% (De 
Angelis et al., 2011). EUS is much more effective for localizing intrapancreatic PNETs than 
extrapancreatic PNETs such as duodenal gastrinomas or somatostatinomas. Moreover, EUS 
is particularly helpful in localizing insulinomas, which are small, almost always 
intrapancreatic, and frequently missed by conventional imaging (Kulke et al., 2010a). 
PNETs frequently overexpress somatostatin receptors and bind synthetic somatostatin 
analogues with high affinity. A number of radiolabeled analogues have been developed, 
with the most widely used worldwide and the only one available in the United States 
being 111In-DTPA-octreotide (Octreoscan). SRS usually utilizes both planar imaging with 
either whole body scanning or multiple static acquisitions and single-photon computed 
tomography (SPECT). The latter modality can potentially improve the accuracy of SRS. This 
can allow SRS to detect up to 50% to 70% of primary PNETs and more than 90% of patients 
with metastatic disease. False-positive localizations can occur in up to 12% of patients, so it 
is important to interpret the results cautiously (Dabizzi et al., 2010; Kulke et al., 2010a) .  
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6. Role of surgery and liver directed therapy 
The therapeutic plan of PNETs is based on the histologic classification and tumor stage. 
Surgery remains the cornerstone of treatment of early stage PNETs. Surgical resection of 
localized PNETs offers excellent prognosis and curative potential. Depending on the site 
and size, in the absence of distant metastases enucleation may be sufficient. This approach 
can easily be employed for many PNETs specially insulinomas, small non functioning 
PNETs (<2 cm) and small gastrinomas (Kulke et al., 2010a) . The long term survival in 
certain cases may exceed 90% (Service et al., 1991). Whipple pancreatoduodenectomy, left 
pancreatectomy or total pancreatectomy can offer a 5-year survival rates of 61%-79% even in 
some advanced cases (Dabizzi et al., 2010). The role of surgery in patients with MEN1 
syndrome is complicated and remains controversial because the risk of additional 
neoplasms within the remaining pancreas and other sites (Demeure et al., 1991).  
In patients with limited hepatic metastases, surgical hepatic resection may be feasible to 
debulk the tumor burden and help alleviate symptoms. Surgical resection of majority of the 
tumor is possible in only 5-15% of PNETs with hepatic metastases (Norton, 2005; Que et al., 
2006). This approach can offer improvement in symptoms in over 90% of patients 
(Sarmiento and Que, 2003).Even though most of the evidence in this area is derived from 
uncontrolled studies, many agree that surgical resection should be attempted in malignant 
PNET with limited hepatic metastases if it is deemed possible that >90% of viable tumor can 
be removed (Kulke et al., 2010a). 
In patients who are not candidates for surgical hepatic resection, hepatic arterial 
embolization remains a viable palliative approach. Important characteristics that are 
important for patient consideration is a preserved performance status , liver confined 
disease and a patent portal vein. Response rates are generally encouraging ( >50% ) as 
measured by either radiographic regression or hormonal secretion (Gupta et al., 2003; 
O'Toole and Ruszniewski, 2005; Toumpanakis et al., 2007). Although a number of 
techniques exist, including bland embolization, chemo-embolization or radioisotope-
embolization, no data exist determining the superiority of one approach over another.  
Other radiological approaches that can be employed in treating the hepatic metastases in 
malignant PNET, are radiofrequency ablation and cryoablation (Toumpanakis et al., 2007). 
These approaches may not be a feasible option in bulky hepatic disease and the benefit 
derived in small volume disease is also not clear. The advantage may be that these 
techniques seem to cause less morbidity. Therefore, careful patient selection is crucial to 
consider ablative techniques in order to avoid any unwarranted adverse effects. 
7. Peptide Reception Radiation Technique (PRRT) 
Majority of PNETs express somatostatin receptors, which provides a rationale for PRRT in 
selected cases. The most frequently used radionucleotides for PRRT are yttrium (90Y) and 
lutetium (177Lu), which have different physical and biological characteristics. One study 
reported encouraging results with 129 patients with malignant NETs treated with [177Lu-
DOTA-Tyr3]octreotate and resulted in a complete response in 2%, partial in 32%, and 
stabilization in 34% (Kwekkeboom et al., 2008). This form of treatment is generating 
widespread interest and more randomized studies are warranted in order to better explain 
its efficacy, role and toxicity.  
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8. Role of somatostatin analogs 
The high expression of somatostatin receptors in PNETs also provides a rationale for 
utilizing somatostatin analogs for therapeutic purposes. In the PROMID study, which was a 
randomized, placebo-controlled, prospective trial in patients with midgut carcinoid, 
treatment with somatostatin analog octreotide was associated with improved time to 
progression over placebo (Rinke et al., 2009). Whether this hold true for PNETs, remains to 
be seen and is currently being explored in a number of ongoing studies. According to the 
National Comprehensive Cancer Network guidelines, somatostatin analogs should be 
considered in patients with hormone hypersecretion, although the authors do state that no 
randomized studies to date have demonstrated anti-tumor effect of somatostatin analogs in 
PNETs (Kulke, 2011). Octreotide 150-250 mcg subcutaneously three times a day or 
octreotide LAR 20-30 mg intramuscularly every 4 weeks can be considered for symptom 
control. Short acting octreotide can be added to octreotide LAR for treatment of 
breakthrough symptoms. 
9. Cytotoxic chemotherapy 
A number of chemotherapeutic agents have been tested in advanced metastatic PNETs, with 
encouraging results showing antitumor activity. Streptozocin was approved by the FDA in 
July, 1982 as a treatment for advanced PNET after initial studies showed sufficient 
antitumor effect and response rates. A number of studies by Moertel et al in the 1970’s were 
crucial in this area. One trial randomized 84 patients to either streptozocin alone or 
streptozocin and fluorouracil. Based on non-standard criteria, 63% of patients were reported 
to have a response to therapy, with 33% complete responses in the combination arm 
(Moertel et al., 1980). Other combinations that have been evaluated are 
streptozocin/doxorubicin or streptozocin/doxorubicin/fluorouracil (Kulke et al., 2010a; 
Moertel et al., 1992). Treatment with streptozocin and doxorubicin was associated in a 
combined radiological and biochemical response rate of 69% with a median survival 
approaching 2 years (Moertel et al., 1992). Based on retrospective data, the 3-drug regimen 
of streptozocin, 5-fluorouracil, and doxorubicin is associated with an overall response rate of 
39% and a median survival duration of 37 months (Kouvaraki et al., 2004) .The combination 
of 5-fluorouracil, Cisplatin and streptozocin was tested in a series of 82 patients with 
advanced neuroendocrine tumor, prospectively identified from a database .Sixty percent of 
patients in this series were identified to have a pancreatic primary. Although, limited by a 
number of weaknesses in the study, the investigators reported a response rate of 38% in 
PNETs (Turner et al., 2010). Patients with advanced poorly differentiated PNETs should be 
treated along the small cell carcinoma guidelines with therapy based on platinum regimens. 
This approach has been shown to result in a response rate of 40 to 70% (Kulke et al., 2010a). 
Although, these data support the antitumor activity of streptozocin based regimens, the 
acceptability of this approach has been limited because of a cumbersome administration 
schedule and toxicity profile.  
Temozolomide has been combined with other biological agents such as thalidomide, 
bevacizumab and everolimus is phase II studies, yielding a response rate from 24-45% 
(Kulke et al., 2010b; Kulke et al., 2006a; Kulke et al., 2006b). Moreover, the combination of 
temozolomide and capecitabine has been reported to have an objective response rate of 70% 
(Strosberg et al., 2011) .There is also evidence to suggest that 06-methylguanine DNA 
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methyltransferase (MGMT) deficiency can predict treatment responses to temozolomide in 
PNETs (Kulke et al., 2009b). Considering the available data, temozolomide based treatment 
has comparable efficacy to streptozocin based therapies with favorable toxicity profile. 
Further larger trials are warranted to further elaborate the role of temozolomide in the 
context of modern treatment paradigm in PNET. 
10. Biologically targeted therapies 
Recently, a number of studies have demonstrated activity in PNETs, targeting the vascular 
endothelial growth factor (VEGF) signaling and the mammalian target of rapamycin 
(mTOR) pathways. Although, obejective responses have been persistently low across 
studies, improvements in progression free survival have been encouraging. 
10.1 Targeting VEGF pathway 
PNETs are characterized by upregulation of VEGF and VEGF receptor (VEGFR). This 
correlates with increased angiogenesis, metastases and can potentially lead to decreased 
progression free survival (Zhang et al., 2007). Tyrosine kinase inhibitors with activity 
against VEGFR, such as pazopanib, sorafenib and sunitinib, have been evaluated in 
advanced PNET demonstrating encouraging results. Pazopanib was evaluated in a multi-
instituion phase II study treating a total of 51 patients , 29 of which had PNET. Patients 
received pazopanib 800 mg daily, in addition to octerotide LAR. The response rate among 
patients with PNETs was reported to be 17%. Median PFS was reported to be 11.7 months. 
Grade 3/4 toxicities were relatively rare and included anemia, neutropenia, 
hypertriglyceridemia and liver function derangement (Phan et al., 2010). Another phase II 
trial is evaluating the role of pazopanib in patients with neuroendocrine tumors who may 
have had treatment with antiangiogenic and mTOR inhibitors. The trial is currently accruing 
and is expected to complete accrual in September 2011 (Capdevila et al., 2011). Sorafenib, 
another small molecule tyrosine kinase inhibitor, was evaluated in a phase II study that 
included 43 patients with PNET. Patients received sorafenib 400 mg twice daily. In a 
preliminary analysis, 10% of patients with PNET were observed to have a partial response 
(Hobday et al., 2007).  
Sunitinib was evaluated in a multi-institutional phase II study that included 66 patients with 
PNET. Patients were treated with repeated 6 week cycles of oral sunitinib (50 mg/d) for 4 
weeks followed by 2 weeks off treatment. Overall, objective response rate in PNET was 
observed to be 16.7% . One-year survival rate was reported to be 81% in the PNET group 
(Kulke et al., 2008). Based on encouraging results from this study, a phase III trial to confirm 
the activity of sunitinib was undertaken. Patients were randomized to receive once daily 
oral sunitinib at a dose of 37.5 mg or matching placebo. After enrollment of 171 patients, the 
data safety monitoring committee recommended the discontinuation of study and accrual 
was stopped before the preplanned efficacy analysis. The discontinuation of the study 
precluded definitive hypothesis testing for progression free survival difference between the 
two arms. An analysis of the enrolled patients, 86 of whom received sunitinib and 85 of 
whom received placebo, showed that the median progression free survival was significantly 
longer with sunitinib compared to placebo (11.4 months vs. 5.5 months ; hazard ratio= 0.42; 
p < 0.001). The objective response rate was 9.3% in the sunitinib group vs. 0% in the placebo 
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group. At the data cut off point, the hazard ratio of death was 0.41 (95% CI, 0.19-0.89; 
P=0.02), with 10% of deaths reported in the sunitinib arm compared with 25% of deaths 
reported in the placebo arm (Raymond et al., 2011a). Grade 3/4 adverse events were 
uncommon in the treatment arm with the most common being neutropenia (12%) and 
hypertension (10%). Updated results, however, showed continued favorable trend for 
overall survival in the sunitinib arm but without statistical significance, with a hazard ratio 
of 0.737 (95% CI 0.465- 1.168; p=0.1926) (Raymond et al., 2011b). Based on this trial, FDA 
approved sunitinib for advanced PNET in May, 2011. 
10.2 Targeting mTOR pathway 
mTOR is an intracellular protein kinase which regulates cellular response to nutrients and 
energy in addition to mediating signaling through downstream growth factors such as 
insulin-like growth factor (IGF-1).Sporadic neuroendocrine tumors are known to co-express 
both IGF-1 and its receptor. There is in vitro evidence suggesting stimulation of mTOR 
pathway and inhibition of this pathway has demonstrated tumor regression in preclinical 
models (von Wichert et al., 2000; Yao, 2007). Temsirolimus and everolimus are rapamycin 
derivatives that have been tested in PNET. Temsirolimus was evaluated in a phase II clinical 
trial in advanced neuroendocrine tumors which included 15 patients with PNET. Partial 
response rate of 6.7% was observed in the PNET patient population (Duran et al., 2006). In 
an initial phase 2 study the combination of everolimus and octerotide was evaluated, 
reporting a partial response of 27% in patients with PNET (Yao et al., 2008b). The activity of 
everoliumus was subsequently evaluated in an international phase II multicenter trial 
(RADIANT-1). A total of 160 patients with advanced PNET were enrolled into the study. In 
this non randomized study, treatment with everolimus was associated with an overall 
response rate of 4.4% and progression free survival duration of 16.7 months in patients 
receiving concomitant octerotide. In patients not receiving octerotide, the response rate was 
9.6% and progression free survival duration was 9.7 months (Yao et al., 2010a). This was 
followed by an international phase III randomized clinical trial (RADIANT 3) assigning 410 
patients to receive treatment with everolimus or placebo. Everolimus was administered as 
10 mg once daily, in conjunction with best supportive care. Octreotide was given at the 
discretion of the investigator. More than 80% of patients had well differentiated disease and 
more than 90% had metastases to liver. The median progression free survival as assessed by 
the local investigator was 11 months in the everolimus group as compared to 4.6 months in 
the placebo arm (hazard ratio 0.35; 95% CI 0.27-0.45; p<0.001). Grade 3/4 adverse events 
were rare in the treatment group which included anemia (6%) and hyperglycemia (5%). The 
overall tumor response rate associated with everolimus in this study was 5% (Yao et al., 
2011). Based on this trial, the FDA approved everolimus for advanced PNET in May, 2011. 
11. Combination strategies 
Strategies to combine biological agents have begun in patients with advanced PNET. In a 
phase II trial, the combination of everolimus and bevacizumab was recently shown to be 
well tolerated and associated with an overall response rate of 26% in low to intermediate 
grade neuroendocrine tumors (Yao et al., 2010b). CALGB 80701 is currently randomizing 
patients with advanced PNET to receive either treatment with everolimus or everolimus + 
bevacizumab, to asses efficacy and toxicity. This trial will hopefully shed more light on the 
role for combination strategy in the treatment armamentarium for PNET. 
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12. Conclusions 
PNETs are a heterogeneous group of rare tumors with a wide range of biological activity, 
manifestation and variable prognosis. Accurate clinical, pathologic and histologic diagnosis 
is an important first step in developing an appropriate management plan. PNETs should be 
considered separately from carcinoid tumors as they are dissimilar in clinical behavior, 
response to treatment and prognosis. Surgical resection remains the mainstay of treatment 
for early stage disease. Advanced PNET often requires a multidisciplinary approach. 
Options for advanced stage include liver directed therapies including surgery and 
radioembolization techniques. Systemic treatment option include somatostatin analogs for 
symptom control, cytotoxic chemotherapy (temozolomide or streptozocin based regimens) 
and molecularly targeted agents (sunitinib and everolimus). No specific treatment sequence 
currently exists. Future studies will provide more insight into combination strategies and 
expand our treatment options for patients with this disease. 
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